by Maria Zannes | Oct 11, 2024 | Articles, News
The Alamo City company has gained new commercial access that could greatly expand its reach and its revenue. As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. has reached a...
by Maria Zannes | Jul 3, 2024 | Articles, News
bioAffinity Technologies News Update SAN ANTONIO, Texas (July 3, 2024) – We are pleased to share the latest updates from bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) as we continue to accelerate the commercialization of CyPath® Lung, our noninvasive diagnostic...
by Maria Zannes | Nov 8, 2023 | Articles, News
The latest move is a key step for an Alamo City company pursuing widespread adoption of its core technology. As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Nov. 6, 2023 San Antonio-based bioAffinity...
by Maria Zannes | Sep 27, 2023 | Articles, News
Sept. 26, 2023 As published in 360Dx By Greg Cima NEW YORK – bioAffinity has its eyes on expanding sales of its sputum-based lung cancer test nationwide through its recent acquisition of the pathology laboratory that had licensed and developed that technology into a...
by Maria Zannes | May 8, 2023 | Articles, News
bioAffinity Technologies CEO Maria Zannes says the company has made a key hire May 4, 2023 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. has made a key change in its...
by Maria Zannes | Mar 6, 2023 | Articles, News
MARCH 6, 2023 The Empowered Patient podcast host Karen Jagoda recently interviewed bioAffinity Technologies President and CEO Maria Zannes about the development of the CyPath® Lung test for the detection of early-stage lung cancer. Hear the podcast at...
